IHAM
Integral Health Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $18.9M | Hold |
150,000
| – | – | 1.73% | 17 |
|
|
2025
Q1 | $16.6M | Sell |
150,000
-10,000
| -6% | -$1.11M | 1.77% | 14 |
|
|
2024
Q4 | $21.8M | Buy |
+160,000
| New | +$21.8M | 1.86% | 13 |
|
|
2024
Q3 | – | Sell |
-70,000
| Closed | -$9.64M | – | 87 |
|
|
2024
Q2 | $9.64M | Sell |
70,000
-80,000
| -53% | -$11M | 0.92% | 34 |
|
|
2024
Q1 | $20.7M | Buy |
150,000
+60,000
| +67% | +$8.28M | 1.92% | 16 |
|
|
2023
Q4 | $11.9M | Buy |
90,000
+5,000
| +6% | +$659K | 1.62% | 23 |
|
|
2023
Q3 | $9.56M | Buy |
+85,000
| New | +$9.56M | 1.32% | 29 |
|
|
2022
Q4 | – | Sell |
-90,000
| Closed | -$9.56M | – | 83 |
|
|
2022
Q3 | $9.56M | Buy |
+90,000
| New | +$9.56M | 1.86% | 19 |
|
|
2022
Q2 | – | Sell |
-35,000
| Closed | -$3.28M | – | 79 |
|
|
2022
Q1 | $3.28M | Buy |
+35,000
| New | +$3.28M | 0.85% | 42 |
|
|
2020
Q3 | – | Sell |
-20,000
| Closed | -$2.44M | – | 82 |
|
|
2020
Q2 | $2.44M | Buy |
+20,000
| New | +$2.44M | 0.73% | 47 |
|
|
2020
Q1 | – | Sell |
-15,000
| Closed | -$1.61M | – | 67 |
|
|
2019
Q4 | $1.61M | Buy |
+15,000
| New | +$1.61M | 0.63% | 43 |
|